[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Roy, Anjali and Srivastava, Mansi and Saqib, Uzma and Liu, Dongfang and Faisal, Syed M. and Sugathan, Subi and Bishnoi, Suman and Baig, Mirza S. (2016) Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways. International Immunopharmacology, 40. pp. 79-89. ISSN 15675769


Download (1274Kb) | Preview


Inflammation is set off when innate immune cells detect infection or tissue injury. Tight control of the severity, duration, and location of inflammation is an absolute requirement for an appropriate balance between clearance of injured tissue and pathogens versus damage to host cells. Impeding the risk associated with the imbalance in the inflammatory response requires precise identification of potential therapeutic targets involved in provoking the inflammation. Toll-like receptors (TLRs) primarily known for the pathogen recognition and subsequent immune responses are being investigated for their pathogenic role in various chronic diseases. A mammalian homologue of Drosophila Toll receptor 4 (TLR4) was shown to induce the expression of genes involved in inflammatory responses. Signaling pathways via TLR4 activate various transcription factors like Nuclear factor kappa-light-chain-enhancer (NF-κB), activator protein 1 (AP1), Signal Transducers and Activators of Transcription family of transcription factors (STAT1) and Interferon regulatory factors (IRF's), which are the key players regulating the inflammatory response. Inhibition of these targets and their upstream signaling molecules provides a potential therapeutic approach to treat inflammatory diseases. Here we review the therapeutic targets involved in TLR-4 signaling pathways that are critical for suppressing chronic inflammatory disorders.

Item Type: Article
Subjects: Animal Genetics and Genomics
Depositing User: Mr Harjit Singh
Date Deposited: 20 Nov 2018 09:32
Last Modified: 24 Apr 2019 05:10
URI: http://niab.sciencecentral.in/id/eprint/25

Actions (login required)

View Item View Item